Boehringer Ingelheim inks third collab in four years with Danish biotech company

Another deal has fallen into place between Boehringer Ingelheim and the Danish biotech and contract research firm Gubra. The parties have entered into lucrative deals in the past, but will not disclose the financial terms underlying the new agreement.

Photo: Gubra / PR

Danish biotech and contract research firm Gubra has signed a new agreement with German pharmaceutical giant Boehringer Ingelheim on the development of peptide compounds for treating obesity, according to a joint press announcement from the companies.

Thus, the two firms continue the collaboration between them which has been going on since 2017. Neither party wishes to disclose the financial terms behind the new deal, but the company's two former deals had lucrative potentials.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs